Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
Earnings Data
Report Date
Apr 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.03Last Year’s EPS
-2.88Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 33.73%
|Next Earnings Date:Apr 04, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment with notable achievements in revenue growth, cost reduction, and product approval, juxtaposed with challenges such as Hurricane Milton's impact, legal expenses, and ongoing losses.Company Guidance
During the Biofrontera Inc. third quarter 2024 conference call, management outlined key metrics and developments. Revenue for the quarter rose by 1.5% to $9 million, with a delay affecting 4,640 tubes of Ameluz worth $1.5 million due to Hurricane Milton. Without this delay, revenue growth would have been 19%. For the first nine months, sales increased by 5.6% to $24.8 million, potentially reaching 12% growth without the hurricane's impact. Operating expenses were $14 million, with a net loss of $5.7 million. Adjusted EBITDA was negative $4.6 million. The company reduced SG&A expenses by 14% and saw FDA approval for the use of up to three Ameluz tubes per treatment, enhancing flexibility for healthcare providers. Additionally, Biofrontera launched the RhodoLED XL lamp and reported encouraging Phase 3 trial results for superficial basal cell carcinoma. Cash and cash equivalents stood at $2.9 million as of September 30, 2024.Revenue Growth Despite Delays
Revenues in Q3 increased by 1.5% to $9 million. Without delays due to Hurricane Milton, growth would have been 19%. For the first nine months, sales grew by $1.3 million to $24.8 million, an increase of 5.6%.
Reduced Costs and Improved Profitability
SG&A expenses were reduced by 14% in the first nine months compared to last year. A reduced transfer price for Ameluz has been negotiated, enhancing profitability.
FDA Approval for Ameluz
FDA approved the use of up to three tubes of Ameluz per treatment, enhancing treatment flexibility and potential market share.
Encouraging Clinical Trial Results
Outstanding clinical results for new indications, including a 75.9% clearance in a BCC Phase 3 study, with submission to FDA expected in mid-2025.
Successful Product Launch
Launched RhodoLED XL lamp, with 39 units installed since June, contributing to revenue.
---
BFRI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BFRI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.83 | $0.70 | -15.66% |
| Aug 14, 2024 | $1.14 | $1.16 | +1.75% |
| May 15, 2024 | $1.21 | $1.09 | -9.92% |
| Mar 15, 2024 | $1.55 | $1.26 | -18.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biofrontera (BFRI) report earnings?
Biofrontera (BFRI) is schdueled to report earning on Apr 04, 2025, TBA Not Confirmed.
What is Biofrontera (BFRI) earnings time?
Biofrontera (BFRI) earnings time is at Apr 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BFRI EPS forecast?
BFRI EPS forecast for the fiscal quarter 2024 (Q4) is -0.03.
---